A case of pulmonary alveolar microlithiasis occurring in an inbred family is presented. A genome-wide analysis of the patient's genomic DNA using a high-density single nucleotide polymorphism (SNP) array revealed a small intragenetic mutation at SLC34A2. The results suggest that the high-density SNP array has the power to identify a recessive disease gene(s) even in the analysis of only a single inbred patient.
Inbreeding increases the chance for a mutant gene to become homozygous in the offspring and thus for autosomal recessive diseases to develop. 1 The increased homozygosity is attributed to the appearance of chromosomal regions called autosomal segments, 2 where both strands of homologous chromosomes are identical by descent (ie, derived from a single chromosome of a single ancestor). In inbred children affected by an autosomal recessive disease, the causative gene is very likely to be in the autozygous segments. 3 4 Recent high-density single nucleotide polymorphism (SNP) arrays are able to determine both of the SNP genotypes genome-wide and the copy number of each chromosomal location. A patient with pulmonary alveolar microlithiasis was investigated using the array which revealed a small intragenetic deletion in the SLC34A2 gene, the gene considered to be the cause of the disease.
CASE REPORT
A 56-year-old woman was admitted to hospital with progressive dyspnoea, severe systemic oedema and a weight increase from 45 kg to 60 kg. She had been notified for the first time in her 30s that her chest radiograph was abnormal although, at that time, no subjective symptoms were present. A physical examination showed blood pressure 128/60 mm Hg, pulse rate 84 bpm and arterial oxygen saturation (SpO 2 ) measured with a pulse oximeter of 90%. Her pulmonary second heart sound was accentuated. Laboratory test results revealed increased serum levels of C-reactive protein (2.3 mg/dl), B-type natriuretic peptide (1256 pg/ml) and sialylated carbonhydrate antigen KL-6 (583 U/ml). A chest radiograph revealed numerous micronodules throughout the entire lung field and obscured the cardiac shadow ( fig 1A) . A CT scan of the chest showed consolidation and diffuse ground-glass opacities in both lungs, accompanied by dilated bronchi ( fig 1B, upper panel) . A marked enlargement of the right heart, retention of pleural and pericardial effusions and calcification involving the mediastinal and interlobular pleura and the pericardium were also observed ( fig 1B, lower panel) . The ECG revealed a right bundle branch block accompanied by a tall R wave in aV R and V 1 , deep S and a small r in I and aV L and a persistent S or s in the left precardial leads. These findings suggested right ventricular hypertrophy. Spirometry showed restrictive ventilatory disturbances (vital capacity 51.6%, forced expiratory volume in 1 s 93.1%). 
Genome-wide SNP study
A genome-wide SNP study was performed using an SNP Array 6.0 (Affymetrix, USA) which genotypes 906 600 SNPs and determines the copy number of the chromosomal sequences at 946 000 chromosomal locations. 5 Autozygous segments were predicted from the genotyping data ( fig 1E) . All genes contained in the segments are homozygous and therefore recessive traits may reveal themselves in the phenotype. SLC34A2, a causative gene for PAM, was located in an autozygous segment on chromosome 4. The copy number data showed that the sequence at probe CN_1062321 was absent, suggesting that the segment it locates was homozygously deleted (fig 1F) . A detailed PCR analysis confirmed a 5.5 kb long homozygous deletion that involved exons 2-6 of the SLC34A2 gene and thus caused PAM in this patient.
DISCUSSION
PAM is an autosomal recessive disease with more than 500 patients reported worldwide 6 7 and with the mutation of SLC34A2 identified as the cause. 8 9 The whole genome analysis showed the power of a recently developed SNP genotyping platform. If it is assumed that SLC34A2 was not known to be the causative gene for PAM, since the autozygous segments often contain the recessive disease genes, the autozygous segments could have been analysed to search for the chromosomal aberrations that affect the function of some genes which might have led to the deletion at SLC34A2. This shows that the analysis with a single inbred patient may identify a causative gene. By January 2007, only 2000 out of 22 000 human genes have been associated with a disease; 10 many of the recessive genes are considered to be unidentified, especially those that cause diseases with a low penetrance or that occur only in elderly persons. When a distinct disease is seen in an inbred patient, a whole genome SNP study may be worth trying. Data obtained from only a single patient may therefore provide a clue to the causative gene. Copy number probes at the SLC34A2 locus determined by an SNP array 6.0, the SLC34A2 genomic structure and the scale that starts from the telomere of the short arm of chromosome 4 are shown aligned. Log 2 ratio indicates the copy number of chromosomes at each position, ie, 0 (nulliploid), 1 (haploid), 2 (duploid) or 4 (tetraploid). Log 2 ratio of the probe CN_1062321 is 0 (nulliploid) while the copy number of the adjacent probes CN_1062320 and CN_1062322 is 2 (diploid), suggesting the presence of a homozygous deletion at CN_1062321. PCR reactions that amplify each exon of SLC34A2 failed to amplify exons 2-6 (shown by 6) and confirm the presence of a homozygous deletion. The nucleotide sequences of other exons and their flanking sequences have been confirmed to be the wild-type sequences.
Procalcitonin-guided antibiotic use for respiratory tract infections
Antibiotic therapy is widely used in primary care to treat acute respiratory tract infections in spite of predominant viral aetiology. This study investigated whether procalcitonin (PCT), a biochemical marker elevated in systemic bacterial infections, can be used to guide antibiotic treatment.
A total of 458 adults with respiratory tract infection symptoms who, in their physician's opinion required antibiotics, were included. Patients were randomised to PCT-guided or standard antibiotic therapy. Antibiotic use in the PCT-guided therapy arm was related to raised serum levels. Follow-up data were collected at 7, 14 and 28 days after presentation. The primary outcome measure was the number of days of patient inactivity. Secondary outcome measures included antibiotic prescription rates and duration of treatment.
There was no difference in the number of days with restricted activities between the two groups. A 40% reduction in antibiotic prescriptions was found in the PCT-guided group in those patients with an acute exacerbation of COPD, asthma or community acquired pneumonia, and an 80% reduction in those with upper respiratory tract infections or acute bronchitis. Interestingly, 15% of patients received antibiotics in the PCT group despite PCT levels being below the cut-off level.
The authors concluded that PCT-guided treatment did not compromise patient outcome in acute respiratory tract infections. However, patients were not blinded, possibly leading to bias in those who did not receive antibiotics. PCT could be used in the future to guide treatment and to reduce antibiotic use which, in turn, may help to decrease antibiotic resistance. However, changing physicians' methods of practice may prove a trickier task. 
